课题基金 / 基金详情

Medication Continuity in Children Treated for ADHD

Medication Continuity in Children Treated for ADHD
治疗多动症儿童的药物连续性
批准号:
8585881
负责人:
William Bernard Brinkman
金额:
$17.43万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-01-01 至 2015-03-16

项目摘要

项目成果

William Bernard Brinkman的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): This Mentored Patient-Oriented Research Career Development Award (K23) program is designed to develop expertise for becoming an independent investigator in the study of medication continuity in children with Attention-Deficit/Hyperactivity Disorder (ADHD) cared for in primary care settings. This is a critical area because despite the proven efficacy of stimulant medications to reduce ADHD symptoms, many children discontinue treatment, thereby preventing them from realizing the full therapeutic benefits of treatment and this contributes to unnecessary suffering for children and their families. The ultimate goal is to develop the expertise needed to develop evidence-based, personalized interventions to improve medication continuity among children and adolescents with ADHD. The Candidate's strong background of research and clinical training in pediatrics, education, and research provides an excellent foundation for this work. The proposed training goals include enhancing skills in the following areas: 1) biostatistical modeling with longitudinal data; 2) adherence measurement; 3) design and implementation of interventions for ADHD; 4) development of psychological, adherence, and family/self management interventions; 5) grant writing and presentation of scientific data. Achieving these training goals is essential to the Candidate's success in transitioning to independence as an investigator who pursues methodologically sound, technically feasible, and innovative approaches to intervention research in this population. The objective of the research plan is to better understand the factors that promote medication continuity in children with ADHD. A prospective, longitudinal cohort of 100 children 6-10 years old started on medicine for ADHD by their primary care doctor. The cohort will be recruited from 21 physicians in 7 practices. We will collect four waves of data over 18 months to address the following specific aims: Aim 1: Describe medication continuity in a community-based clinical cohort of children treated for ADHD. Aim 2: Identify reasons parents stop and re-start their child's medication treatment. Aim 3: Determine relationship between factors that influence family decision making and medication continuity. The Candidate plans to achieve his goal by translating knowledge gained from this study to 1) segment the population at risk for poor medication continuity and, 2) develop personalized interventions that target modifiable factors important to promote medication continuity.
期刊论文(11)
专著(0)
科研奖励(0)
会议论文
Strategies for improving ADHD medication adherence.
提高多动症药物依从性的策略。
DOI: --
发表时间: 2019
期刊: Current psychiatry
影响因子: --
作者: [Kamimura-Nishimura,KellyI, Brinkman,WilliamB, Froehlich,TanyaE]
通讯作者: Froehlich,TanyaE
Study protocol: a systematic review of pediatric shared decision making.
研究方案:对儿科共同决策的系统评价。
DOI: 10.1186/2046-4053-2-48
发表时间: 2013
期刊: Systematic reviews
影响因子: 3.7
作者: [Wyatt,KirkD, PrutskyLopez,Gabriela, DomecqGarces,JuanPablo, Erwin,Patricia, Brinkman,WilliamB, Montori,VictorM, LeBlanc,Annie]
通讯作者: LeBlanc,Annie
DOI: 10.1136/bmjqs-2013-002179
发表时间: 2014-06
期刊: BMJ quality & safety
影响因子: 5.4
作者: [Brady PW, Brinkman WB, Simmons JM, Yau C, White CM, Kirkendall ES, Schaffzin JK, Conway PH, Vossmeyer MT]
通讯作者: Vossmeyer MT
DOI: 10.1186/1546-0096-11-34
发表时间: 2013-09-30
期刊: Pediatric rheumatology online journal
影响因子: --
作者: [Lipstein EA, Brinkman WB, Sage J, Lannon CM, Morgan Dewitt E]
通讯作者: Morgan Dewitt E
Developing New Technologies to Improve ADHD Medication Continuity For PAR 12-279
  • 批准号:
    8824969
  • 项目类别:
  • 资助金额:
    $23.4万
  • 财政年份:
    2014
  • 负责人:
    William Bernard Brinkman
  • 依托单位:
Developing New Technologies to Improve ADHD Medication Continuity For PAR 12-279
  • 批准号:
    8700812
  • 项目类别:
  • 资助金额:
    $27.3万
  • 财政年份:
    2014
  • 负责人:
    William Bernard Brinkman
  • 依托单位:
Developing New Technologies to Improve ADHD Medication Continuity For PAR 12-279
  • 批准号:
    9038444
  • 项目类别:
  • 资助金额:
    $19.5万
  • 财政年份:
    2014
  • 负责人:
    William Bernard Brinkman
  • 依托单位:
Medication Continuity in Children Treated for ADHD
  • 批准号:
    8197016
  • 项目类别:
  • 资助金额:
    $17.65万
  • 财政年份:
    2010
  • 负责人:
    William Bernard Brinkman
  • 依托单位:
海外基金